IGLL5 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:100423062, HGNC:38476, IGL, IGLL5, IGLV, NM_001178126, NM_001256296, NP_001171597, NP_001243225, VL-MAR, immunoglobulin lambda like polypeptide 5

Id:ENSG00000254709

Hgnc:HGNC:38476

Entrez:100423062

Ensembl:ENSG00000254709

Description:immunoglobulin lambda like polypeptide 5

This gene encodes one of the immunoglobulin lambda-like polypeptides. It is located within the immunoglobulin lambda locus but it does not require somatic rearrangement for expression. The first exon of this gene is unrelated to immunoglobulin variable genes; the second and third exons are the immunoglobulin lambda joining 1 and the immunoglobulin lambda constant 1 gene segments. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2010]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View IGLL5's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with IGLL5.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using IGLL5.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for IGLL5.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with IGLL5.

Results found

Linked to

	Label	Description
	GSE135350 2 V 4 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 etoposide leukocyte 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 4 V 1 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 3 V 5 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE151612 4 V 2 PRACINOSTAT HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE176366 vincristine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE126463 pomalidomide MM1.S 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE115384 CELSR2 knockdown 5 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE95077 amiloride 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE174498,GSE174500 5 V 8 ASPARAGINASE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE135350 2 V 4 DEXAMETHASONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE120612 etoposide leukocyte 6 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE120612 4 V 1 ETOPOSIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE135350 3 V 5 DEXAMETHASONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE151612 4 V 2 PRACINOSTAT HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE176366 vincristine 3 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE126463 pomalidomide MM1.S 0 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE115384 CELSR2 knockdown 5 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE95077 amiloride 1 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE174498,GSE174500 5 V 8 ASPARAGINASE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.